Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.41 |
| ▸ | AR | P10275 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | LCLAT1 | Q6UWP7 | 4/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | S1PR1 | P21453 | 5/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4283190 | 1.00 | KDM4E (0.41) | KDM4ERAB9AHSD17B10ARNPC1 | |
| SCHEMBL4280263 | 0.88 | RAB9A (0.40) | KDM4ERAB9AHSD17B10ARNPC1 | |
| SCHEMBL4280270 | 0.88 | RAB9A (0.40) | KDM4ERAB9AHSD17B10ARNPC1 | |
| SCHEMBL4270550 | 0.88 | S1PR1 (0.44) | KDM4ERAB9AHSD17B10NPC1LMNA | |
| SCHEMBL4270556 | 0.88 | S1PR1 (0.44) | KDM4ERAB9AHSD17B10NPC1LMNA | |
| SCHEMBL34465433 | 0.87 | ALDH1A1 (0.41) | KDM4EHSD17B10LMNAALDH1A1HPGD | |
| SCHEMBL4282835 | 0.87 | ALDH1A1 (0.41) | KDM4EHSD17B10LMNAALDH1A1HPGD | |
| SCHEMBL4282838 | 0.87 | ALDH1A1 (0.41) | KDM4EHSD17B10LMNAALDH1A1HPGD | |
| SCHEMBL4271845 | 0.86 | FPR2 (0.41) | ARLCLAT1 | |
| SCHEMBL4271851 | 0.86 | FPR2 (0.41) | ARLCLAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260108497-A1 | OXAZOLE COMPOUND AND PHARMACEUTICAL COMPOSITION | OTSUKA PHARMACEUTICALC., LTD. (JP) | 2026-04-23 | — | — | US | disclosed |
| US-20240148699-A1 | OXAZOLE COMPOUND AND PHARMACEUTICAL COMPOSITION | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2024-05-09 | — | — | US | disclosed |
| US-20220265613-A1 | OXAZOLE COMPOUND AND PHARMACEUTICAL COMPOSITION | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2022-08-25 | — | — | US | disclosed |
| US-20200078340-A1 | OXAZOLE COMPOUND AND PHARMACEUTICAL COMPOSITION | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2020-03-12 | — | — | US | disclosed |
| US-20190070151-A1 | OXAZOLE COMPOUND AND PHARMACEUTICAL COMPOSITION | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2019-03-07 | — | — | US | disclosed |
| US-RE46792-E1 | Oxazole compound and pharmaceutical composition | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2018-04-17 | — | — | US | disclosed |
| US-20170216260-A1 | OXAZOLE COMPOUND AND PHARMACEUTICAL COMPOSITION | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2017-08-03 | — | — | US | disclosed |
| EP-1954684-B1 | OXAZOLE COMPOUND AND PHARMACEUTICAL COMPOSITION | OTSUKA PHARMA CO LTD (JP) | 2014-05-07 | — | — | EP | disclosed |
| US-20140100226-A1 | OXAZOLE COMPOUND AND PHARMACEUTICAL COMPOSITION | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2014-04-10 | — | — | US | disclosed |
| US-8637559-B2 | Oxazole compound and pharmaceutical composition | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2014-01-28 | — | — | US | disclosed |
| US-20090221586-A1 | OXAZOLE COMPOUND AND PHARMACEUTICAL COMPOSITION | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2009-09-03 | — | — | US | disclosed |
| EP-1954684-A2 | OXAZOLE COMPOUND AND PHARMACEUTICAL COMPOSITION | Otsuka Pharmaceutical Co., Ltd. (JP) | 2008-08-13 | — | — | EP | disclosed |
| WO-2007058338-A9 | OXAZOLE COMPOUND AND PHARMACEUTICAL COMPOSITION | OTSUKA PHARMA CO LTD (JP) | 2007-11-01 | — | — | WO | disclosed |
| WO-2007058338-A2 | OXAZOLE COMPOUND AND PHARMACEUTICAL COMPOSITION | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2007-05-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170216260-A1 | OXAZOLE COMPOUND AND PHARMACEUTICAL COMPOSITION | PDE3B, PDE4A, PDE3A | KDM4E 1260/4885RAB9A 4239/4885HSD17B10 552/4885 |
| US-20140100226-A1 | OXAZOLE COMPOUND AND PHARMACEUTICAL COMPOSITION | PDE3B, PDE4A, PDE3A | KDM4E 1260/4885RAB9A 4239/4885HSD17B10 552/4885 |
| US-20240148699-A1 | OXAZOLE COMPOUND AND PHARMACEUTICAL COMPOSITION | PDE3B, PDE4A, PDE3A | KDM4E 1260/4885RAB9A 4239/4885HSD17B10 552/4885 |
| US-20260108497-A1 | OXAZOLE COMPOUND AND PHARMACEUTICAL COMPOSITION | PDE7B, PDE4B, PDE1B | KDM4E 907/4885RAB9A 2305/4885HSD17B10 910/4885 |
| US-20090221586-A1 | OXAZOLE COMPOUND AND PHARMACEUTICAL COMPOSITION | PDE3B, PDE4A, PDE3A | KDM4E 1260/4885RAB9A 4239/4885HSD17B10 552/4885 |
| US-20200078340-A1 | OXAZOLE COMPOUND AND PHARMACEUTICAL COMPOSITION | PDE3B, PDE4A, PDE3A | KDM4E 1260/4885RAB9A 4239/4885HSD17B10 552/4885 |
| US-20220265613-A1 | OXAZOLE COMPOUND AND PHARMACEUTICAL COMPOSITION | PDE3B, PDE4A, PDE3A | KDM4E 1383/4885RAB9A 4352/4885HSD17B10 469/4885 |
| US-20190070151-A1 | OXAZOLE COMPOUND AND PHARMACEUTICAL COMPOSITION | PDE3B, PDE4A, PDE3A | KDM4E 1260/4885RAB9A 4239/4885HSD17B10 552/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.